Medicaid

As a way of assessing the potential future impact of the CPI-based Medicaid Generics Penalty, Bates-White Economic Consulting examined publicly available data on historical drug prices and performed calculations of the potential impact of CPI-based rebates had they been in place in the past. This report shows evidence to suggest that in certain cases, these price regulations may have precisely the opposite of their intended effect.

The ninth annual Generic Drug Access and Savings in the U.S. report demonstrates the vital role that generics and biosimilars play in the United States’ healthcare system. For the first time, the third-party researchers who conducted the study analyzed the differences between brand and generic abandonment behaviors and found some surprising results.